Viral Vector– tag –
-
Vyjuvek Secures UK MHRA Approval; REGENXBIO’s RGX-202 Achieves Primary Endpoint in Duchenne Muscular Dystrophy Phase 3 Trial
YouTube (Lucid Quest) USA Overview A May 28, 2026, update reported that Vyjuvek, a gene therapy for dystrophic epidermolysis bullosa, has received UK MHRA approval. Concurrently, REGENXBIO's RGX-202, a gene therapy for Duchenne muscular ... -
FDA Approves Hepcludex, First Treatment for Chronic Hepatitis Delta Virus (HDV) Infection
FDA (Press Release), European AIDS Treatment Group USA Overview The U.S. FDA has approved Hepcludex (bulevirtide-gmod) injection as the first treatment for chronic hepatitis delta virus (HDV) infection in adults, with or without compensa... -
European Biotechs Drive Next-Gen Cell & Gene Therapy Manufacturing Innovation
BioSpace UK Overview European biotechnology firms are making significant strides in cell and gene therapy (CGT) manufacturing, focusing on scalability and automation. UK-based Oxford Biomedica, a leading viral vector CDMO, specializes in... -
CRISPR Gene Editing Evolves with Cas12a2 to Shred Sick Cell DNA, Expanding Therapeutic Horizons for Cancer and Viral Infections
Top Doctor Magazine USA Overview The CRISPR gene editing landscape is rapidly evolving in 2026, driven by the FDA approval of Cas9-based CASGEVY and the discovery of the novel Cas12a2 protein's ability to 'shred' diseased cell DNA. Unlik... -
Eli Lilly Acquires Engage Biologics for Up to $202 Million to Strengthen Non-Viral DNA Delivery Platform
GuruFocus USA Overview Eli Lilly has agreed to acquire Engage Biologics for up to $202 million, aiming to leverage Engage’s innovative non-viral DNA delivery platform and accelerate the development of next-generation gene therapies. Enga... -
The Future of Healing: Gene Therapy in 2026 Navigates CRISPR Advances and Access Challenges
薬事日報 Japan Overview By 2026, gene therapy is undergoing a paradigm shift, moving towards direct repair or replacement of disease-causing genes. CRISPR-based in vivo editing shows early clinical promise, pushing the vision of single-i... -
NIH-Funded Breakthrough Miniaturizes CRISPR for Precision In Vivo Gene Delivery
National Institutes of Health (NIH) USA Overview An NIH-funded team has discovered and enhanced a remarkably compact CRISPR gene-editing system, Al3Cas12f, enabling precision in vivo delivery. This natural enzyme, small enough to fit wit... -
The In Vivo CAR-T Race Heats Up: Big Pharma Acquisitions and Astellas’ Strategic Collaborations Signal a New Era in Cancer Therapy
Answers（アンサーズ） Japan Overview The global race to develop 'in vivo CAR-T therapy,' which generates CAR-T cells directly within the patient's body, is intensely accelerating as major pharmaceutical companies invest heavily. This inn... -
ProBio and Curocell Achieve BLA Approval for Next-Gen CD19-Targeted CAR-T Therapy, Initiating Commercial Production in South Korea
ProBio CDMO South Korea Overview ProBio CDMO and Curocell have secured Biologics License Application (BLA) approval for anbalcabtagene autoleucel (Anbal-cel; CRC01), their next-generation CD19-targeted CAR-T cell therapy for relapsed or ... -
Ajinomoto Develops Novel Culture Medium Supplement to Boost Gene Therapy Drug Productivity, Accelerating Biomanufacturing Efficiency
味の素株式会社 IRニュース Japan Overview Ajinomoto Group, in collaboration with its U.S. subsidiary Forge Biologics (acquired in 2023 for ~¥82.8 billion), has developed a novel culture medium supplement designed to significantly enhance ...
